Nicotinamide riboside organic acid salt, and preparation therefor and use thereof
The stability and bioavailability issues of nicotinamide riboside α-ketoglutarate were solved by preparing nicotinamide riboside, achieving efficient and environmentally friendly preparation of dietary supplements suitable for tablets, hard capsules and other dosage forms.
Patent Information
- Application Number
- PCT/CN2026/095258
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Nicotinamide riboside has poor chemical stability and low bioavailability. Existing preparation methods use toxic solvents and are not suitable for use in the dietary supplement industry.
The method of forming organic acid salts from nicotinamide riboside and α-ketoglutarate involves reacting in water or organic solvents to generate nicotinamide riboside α-ketoglutarate. The preparation process is simple and uses fewer toxic organic reagents.
It improves the stability and bioavailability of nicotinamide riboside, making it suitable for the dietary supplement industry. The preparation process is high-yield and environmentally friendly.
Smart Images

Figure CN2026095258_12112026_PF_FP_ABST
Abstract
Description
A Nicotinamide Riboside Organic Acid Salt, Its Preparation and Application Technical Field
[0001] This invention belongs to the field of nicotinamide riboside preparation technology, specifically relating to an organic acid salt of nicotinamide riboside and its preparation and application. Background Technology
[0002] Nicotinamide riboside (NR) is an important vitamin B3 derivative. In recent years, it has received widespread attention in the life sciences and health fields. In vivo, nicotinamide riboside participates in key metabolic processes, particularly closely related to the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ is well known to be a coenzyme, playing an indispensable role in many physiological processes such as cellular energy metabolism, DNA repair, and gene expression regulation. With age or in certain disease states, NAD+ levels in the body decline, which has a potential link to the development of age-related diseases and some metabolic disorders. Therefore, nicotinamide riboside supplementation has become a potential intervention to maintain or increase NAD+ levels, thereby improving health or preventing disease. In recent years, nicotinamide riboside has attracted considerable attention as an emerging NAD+ precursor supplement. Nicotinamide riboside chloride has received FDA GRAS certification in the United States, and the chloride salt of NR has been recognized by the FDA as generally safe.
[0003] However, nicotinamide nucleosides have some significant drawbacks and limitations in practical applications. For example, their chemical stability is relatively poor, which may affect their storage, transportation, and effectiveness in practical applications. Furthermore, the bioavailability of nicotinamide nucleosides is not high, but there is still room for improvement to achieve better physiological effects at lower doses.
[0004] Organic acid salts are a class of compound forms widely used in medicinal chemistry and bioactive substance research. By forming salts with organic acids, the physicochemical properties of nicotinamide nucleosides can be improved to some extent. Given the important physiological functions of nicotinamide nucleosides and the limitations of their existing forms, developing organic acid salts of nicotinamide nucleosides that enhance their stability and bioavailability has significant scientific importance and potential application value.
[0005] Chinese invention patent CN 111454311A discloses a method for preparing organic acid salts of nicotinamide ribose. The preparation process requires the addition of methanol and various toxic organic solvents such as methyl tert-butyl ether or ethyl acetate, which is not conducive to its application in the dietary supplement industry. Summary of the Invention
[0006] The present invention aims to provide a nicotinamide riboside organic acid salt with high stability. Another objective of the present invention is to provide a method for preparing the nicotinamide riboside organic acid salt, which can prepare the nicotinamide riboside organic acid salt in high yield and is simple to prepare with fewer organic toxic reagents, making it convenient for use in the dietary supplement industry. A further objective of the present invention is to provide dietary supplements and nicotinamide nucleoside supplements containing the nicotinamide riboside organic acid salt with high stability and better efficacy.
[0007] To achieve the above objectives, the present invention adopts the following technical solution:
[0008] In a first aspect, the present invention provides a nicotinamide riboside organic acid salt, wherein the nicotinamide riboside organic acid salt is nicotinamide riboside alpha-ketoglutarate, and its chemical formula is shown in (I);
[0009] Secondly, the present invention provides a method for preparing nicotinamide riboside organic acid salt, the preparation method comprising the following steps:
[0010] S1. Dissolve nicotinamide riboside in a solvent to obtain solution A, which is nicotinamide riboside;
[0011] S2. Dissolve the organic acid in a solvent, add sodium hydroxide, and mix to obtain solution B, which is an organic acid-basic metal salt;
[0012] S3. Add the nicotinamide riboside solution to the organic acid-base metal salt solution, and the precipitate produced by the reaction is the nicotinamide riboside organic salt.
[0013] Furthermore, in step S1, the nicotinamide nucleoside is nicotinamide nucleoside chloride or nicotinamide nucleoside sulfate.
[0014] Preferably, the nicotinamide nucleoside is nicotinamide hydrochloride.
[0015] Furthermore, in step S2, the organic acid is alpha-ketoglutaric acid.
[0016] Furthermore, in step S3, the molar ratio of the organic acid-base metal salt to nicotinamide riboside is 1:0.9-1.1.
[0017] Furthermore, the solvent for the reaction of the organic acid-base metal salt with nicotinamide riboside is selected from water or an organic solvent.
[0018] Furthermore, the organic solvent is selected from one or any combination of anhydrous ethanol, ethanol, methanol, isopropanol, and acetone.
[0019] Thirdly, the present invention provides the use of nicotinamide riboside organic acid salts prepared by the method described in the first aspect or the second aspect in the preparation of dietary supplements or nicotinamide nucleoside supplements.
[0020] Fourthly, the present invention provides a dietary supplement composed of nicotinamide riboside alpha-ketoglutarate and edible excipients; wherein the nicotinamide riboside alpha-ketoglutarate is the nicotinamide riboside organic acid salt described in the first aspect or the nicotinamide riboside organic acid salt prepared by the method described in the second aspect.
[0021] Furthermore, the edible excipients include galactomannan and vitamin C.
[0022] Furthermore, the weight ratio of the galactomannan to vitamin C is 1:1-2.
[0023] Preferably, the weight ratio of galactomannan to vitamin C is 1:1.
[0024] Furthermore, the weight ratio of the galactomannan to the nicotinamide riboside alpha-ketoglutarate is 1:10-20.
[0025] Preferably, the weight ratio of the galactomannan to the nicotinamide riboside alpha-ketoglutarate is 1:15.
[0026] Furthermore, the dietary supplement can be formulated into various dosage forms suitable for the dietary supplement market, specifically tablets, hard capsules, soft capsules, gels, oral suspensions, etc.
[0027] Fifthly, the present invention provides a nicotinamide nucleoside supplement, wherein the nicotinamide nucleoside supplement is composed of nicotinamide riboside alpha-ketoglutarate and pharmaceutical excipients; wherein the nicotinamide riboside alpha-ketoglutarate is the nicotinamide riboside organic acid salt described in the first aspect or the nicotinamide riboside organic acid salt prepared by the method described in the second aspect.
[0028] Furthermore, the drug can be used alone or in combination with other drugs.
[0029] Furthermore, the drug dosage form is selected from tablets, hard capsules, soft capsules, gels, oral suspensions, etc. Beneficial effects
[0030] The nicotinamide riboside provided by this invention has high stability and activity; the preparation method of the nicotinamide riboside organic acid salt can prepare nicotinamide riboside organic acid salt with high yield, and the preparation process is simple and uses less organic toxic reagents, which is convenient for use in the dietary supplement industry; the dietary supplement containing the nicotinamide riboside organic acid salt provided by this invention has high stability and significantly promotes the efficacy of the active substance nicotinamide riboside organic acid salt. Attached Figure Description
[0031] Figure 1 shows the carbon NMR spectrum of sample 1 from Example 1.
[0032] Figure 2 is an enlarged view of part A in Figure 1.
[0033] Figure 3 is an enlarged view of part B in Figure 1.
[0034] Figure 4 shows the 1H NMR spectrum of sample 1 from Example 1.
[0035] Figure 5 is an enlarged view of part C in Figure 4.
[0036] Figure 6 is an enlarged view of part D in Figure 4.
[0037] Figure 7 shows the results of the locomotion test in 50-day-old fruit flies.
[0038] Figure 8 shows the expression of genes Fkbp12, PRAS40, P300 / nej, and cry in 50-day-old Drosophila.
[0039] Figure 9 shows the climbing ability test results of young fruit flies 10 days after administration of the drug.
[0040] Figure 10 shows the climbing ability test results of young fruit flies 20 days after administration of the drug.
[0041] Figure 11 shows the climbing ability test results of young fruit flies 30 days after administration of the drug.
[0042] Figure 12 shows the climbing ability test results of young fruit flies 40 days after administration of the drug.
[0043] Figure 13 shows the expression of genes Fkbp12, PRAS40, P300 / nej, and cry in young fruit flies.
[0044] Figure 14 shows the ATP / ADP ratio in young fruit flies 20 days after administration.
[0045] Figure 15 shows the ATP / ADP ratio in young fruit flies 40 days after administration. Detailed Implementation
[0046] The technical solution of the present invention will be further described below with specific embodiments, but the scope of protection of the present invention is not limited thereto.
[0047] Example 1 Preparation of Nicotinamide Riboside Organic Acid Salt 1
[0048] This embodiment provides a method for preparing nicotinamide riboside organic acid salt, comprising the following steps:
[0049] 5.0 g of nicotinamide riboside chloride (NR-Cl) was dissolved in 40 mL of anhydrous ethanol under stirring. The reaction was allowed to proceed until clear, and the solution was filtered to obtain solution A. 2.76 g of alpha-ketoglutaric acid was dissolved in 10 mL of anhydrous ethanol. 0.72 g of solid sodium hydroxide was added while stirring and sonicating for 2 hours. The mixture was then filtered to obtain solution B. Solution A (nicotinamide riboside) was added to solution B (an organic acid-basic metal salt) under stirring. After the addition was complete, stirring was continued until the reaction was complete, producing a large amount of precipitate. The precipitate was filtered, dried, and the product 1 was obtained. The yield was 98%.
[0050] NMR and infrared data were measured for sample 1, and subsequent embodiments followed the same measurement method. The measurement results are as follows: NMR and infrared data of sample 1 are as follows:
[0051] Nicotinamide riboside chloride (NR-Cl):
[0052] 13 C NMR (101MHz, D2O) δ165.75,145.64,142.64,140.38,133.91,128.40,99.91,87.63,77.39,69.72,60.17.
[0053] 1 H NMR (400MHz, D2O) δ9.52 (s, 1H), 9.18 (d, J = 7.9Hz, 1H), 8.89 (d, J = 11.1Hz, 1H), 8.23-8.15 (m, 1H), 6.16 (d, J = 4. 5Hz,1H),4.48-4.35(m,2H),4.27(t,J=4.7Hz,1H),3.96(dd,J=12.9,2.9Hz,1H),3.81(dd,J=12.9,3.6Hz,1H).
[0054] Alpha-ketoglutarate (AKG):
[0055] 13 C NMR(101MHz,D2O)δ177.14,173.90,93.58,33.13,28.06.
[0056] 1H NMR (400MHz, D2O) δ2.93 (s, 2H), 2.59 (t, J = 6.6Hz, 2H), 2.35 (t, J = 7.6Hz, 2H), 2.02 (dd, J = 8.3, 7.0Hz, 2H).
[0057] Nicotinamide riboside alpha-ketoglutarate (NR-AKG):
[0058] 13 C NMR (101MHz, D2O) δ177.95,165.74,145.63,142.62,140.37,133.90,128.39,99.90,87.62,77.39,69.71,60.16,33.94,27.74.
[0059] 1 H NMR(400MHz,D2O)δ9.51(d,J=1.7Hz,1H),9.17(dd,J=6.4,1.4Hz,1H),8.88(dt,J=8.1,1.5Hz,1H),8.17(dd,J=8.1,6.3Hz,1H),6.15(d,J=4.4H z,1H),4.45-4.34(m,2H),4.26(t,J=4.6Hz,1H),3.95(dd,J=12.9,2.9Hz,1H),3.80(dd,J=13.0,3.6Hz,1H),2.87(s,2H),2.56(t,J=6.6Hz,2H).
[0060] Infrared spectral data: 112507-NRCL Batch No.: IGT04HM20240519
[0061] IR(CM-1):3304.42,3234.70,3146.77,1701.38,1666.87,1647.96,1510.84,1435.57,1398.63,1262.45,1178.43,1100. 17,1060.99,1034.53,986.03,926.10,898.45,851.70,830.52,779.48,760.63,734.51,667.93,607.92,580.58,484.95;
[0062] 112507-a-Ketoglutaric Acid Batch No.: 20241007-2
[0063] IR(CM-1):2916.49,2661.33,1686.21,1441.62,1423.10,1405.83,1319.36,1274.30, 1224.95,1091.38,1045.10,871.32,809.83,737.40,680.13,640.12,560.18,505.80;
[0064] 112507-NRCL+-a-Ketoglutaric 1:1 Mixture, Lot No.: 20241115
[0065] IR(CM-1):3234.03,3142.06,2964.86,1698.28,1666.86,1647.48,1581.53,1510.58,1397.49,1288.97,1262.24,1178.0 6,1134.35,1095.50,1034.18,985.06,925.71,895.33,847.95,830.21,759.85,671.42,637.60,610.34,528.03,453.10;
[0066] 112507-Nicotinamide Riboside Alpha-Ket oglutarate Batch No.: NRAKG241024P01
[0067] IR(CM-1):3052.40,1694.40,1626.46,1445.72,1416.73,1319.23,1227.65, 1102.55,1053.87,900.59,869.93,848.67,765.95,697.46,672.21,651.58.
[0068] A comparison of the CMR data of nicotinamide riboside alpha-ketoglutarate with those of nicotinamide riboside and AKG NMR shows that the chemical shift of C1 in alpha-ketoglutarate is significantly altered due to deshielding. A comparison of the H1N M data of nicotinamide riboside alpha-ketoglutarate with those of nicotinamide riboside and AKG NMR shows that the chemical shifts of certain protons around the nitrogen atom in nicotinamide riboside are significantly altered.
[0069] Combining Figures 1-3 and 4-6 with the changes in chemical shifts in the above NMR data indicates that the chemical environment of each atom in nicotinamide riboside and AKG has changed, suggesting that the two combine to form nicotinamide riboside alpha-ketoglutarate.
[0070] Example 2 Preparation of Nicotinamide Riboside Organic Acid Salt 2
[0071] This embodiment provides a method for preparing nicotinamide riboside organic acid salt, which is the same as in Example 1, except that the nicotinamide riboside type is changed to nicotinamide sulfate riboside, to obtain nicotinamide riboside alpha-ketoglutarate. The method includes the following steps:
[0072] 5.0 g of nicotinamide riboside sulfate was dissolved in 40 mL of anhydrous ethanol under stirring. The reaction was allowed to proceed until clear, and the solution was filtered to obtain solution A. 2.76 g of alpha-ketoglutarate was dissolved in 10 mL of anhydrous ethanol. 0.72 g of solid sodium hydroxide was added while stirring and sonicating for 2 hours (avoiding water ingress during the process). The solution was filtered to obtain solution B. Solution A was added dropwise to solution B under stirring. After the addition was complete, stirring was continued until the reaction was complete, producing a large amount of precipitate. The precipitate was filtered, dried, and the product 2 was obtained. The yield was 88%.
[0073] Example 3 Preparation of Nicotinamide Riboside Organic Acid Salt 3
[0074] This embodiment provides a method for preparing nicotinamide riboside organic salt, which is the same as in Example 1, except that the molar ratio of the organic acid-base metal salt to nicotinamide riboside chloride is adjusted to 1:0.9, thus obtaining the nicotinamide riboside organic salt. The yield is 96%.
[0075] Example 4 Preparation of Nicotinamide Riboside Organic Acid Salt 4
[0076] This embodiment provides a method for preparing nicotinamide riboside organic salt, which is the same as in Example 1, except that the molar ratio of the organic acid-base metal salt to nicotinamide riboside chloride is adjusted to 1:1.1 to obtain the nicotinamide riboside organic salt. The yield is 95%.
[0077] Comparative Example 1: Preparation of Nicotinamide Riboside Organic Acid Salt 5
[0078] This embodiment provides a method for preparing nicotinamide riboside organic salts. The preparation method is the same as in Example 1, except that sodium hydroxide is not used. All other steps remain the same, but this method cannot prepare nicotinamide riboside organic salts.
[0079] Example 5 Preparation of Nicotinamide Riboside Organic Acid Salt 6
[0080] This embodiment provides a method for preparing nicotinamide riboside organic salts, which is the same as in Example 1, except that the organic solvent is adjusted to be an equal amount of isopropanol, to obtain nicotinamide riboside organic salts. The yield is 93%.
[0081] Example 6 Preparation of Nicotinamide Riboside Organic Acid Salt 6
[0082] This embodiment provides a method for preparing nicotinamide riboside organic salt. The preparation method is the same as in Example 1, except that the organic solvent is adjusted to be an equal amount of acetone, in order to prepare nicotinamide riboside organic salt.
[0083] Statistical analysis of Examples 1-6 revealed that nicotinamide riboside organic salts were successfully prepared in all examples, but the highest yield was achieved under the conditions of Example 1, while the yields of Examples 3-6 all showed a certain decrease.
[0084] Example 7 Dietary Supplement 1
[0085] This embodiment provides a dietary supplement comprising 500 mg of nicotinamide riboside alpha-ketoglutarate prepared in Example 1, 50 mg of galactomannan, and 50 mg of vitamin C; wherein the weight ratio of galactomannan to the nicotinamide riboside alpha-ketoglutarate is 1:10.
[0086] Example 8 Dietary Supplement 2
[0087] This embodiment provides a dietary supplement comprising 500 mg of nicotinamide riboside alpha-ketoglutarate prepared in Example 1, 33.33 mg of galactomannan, and 33.33 mg of vitamin C; the weight ratio of galactomannan to vitamin C is 1:1, wherein the weight ratio of galactomannan to the nicotinamide riboside alpha-ketoglutarate is 1:15.
[0088] Example 9 Dietary Supplement 3
[0089] This embodiment provides a dietary supplement comprising 500 mg of nicotinamide riboside alpha-ketoglutarate prepared in Example 1, 25 mg of galactomannan, and 25 mg of vitamin C; the weight ratio of galactomannan to vitamin C is 1:1, wherein the weight ratio of galactomannan to the nicotinamide riboside alpha-ketoglutarate is 1:20.
[0090] Comparative Example 2: Dietary Supplements 4
[0091] A dietary supplement with the same components as in Example 7, except that 500 mg of nicotinamide riboside alpha-ketoglutarate is replaced with an equal amount of nicotinamide riboside and alpha-ketoglutarate, while the other components remain unchanged.
[0092] Comparative Example 3: Dietary Supplement 5
[0093] A dietary supplement with the same components as in Example 7, except that it does not contain galactomannan, while the other components remain unchanged.
[0094] Example 10 Stability Test
[0095] In this embodiment, stability tests were conducted on Examples 7-9 and Comparative Examples 2-3. The test method is as follows: A dietary supplement prepared in Examples 7-9 and Comparative Examples 2-3 was placed under accelerated conditions of 40°C and 75% RH for 0, 1, 3 and 6 months, and accelerated stability was examined in accordance with the guidelines for stability testing of Chinese Pharmacopoeia preparations.
[0096] The experimental results show that after 6 months, the effective substance content of the mixture of nicotinamide riboside alpha-ketoglutarate, galactomannan and vitamin C is greater than 98%. Among them, the stability is the highest, greater than 99.56%, when the weight ratio of galactomannan to nicotinamide riboside alpha-ketoglutarate is 1:15. In contrast, the effective substance content of Comparative Examples 2 and 3 is less than 85% after 6 months. This shows that the stability of this dietary additive is significantly improved.
[0097] Example 11: Verification of the effect of nicotinamide riboside organic acid salt
[0098] 1. Results of 10-day treatment in 50-day-old fruit flies
[0099] Select 50-day-old w Dah Female fruit flies were administered either NR-Cl (nicotinamide riboside chloride) or NR-AKG (nicotinamide riboside-α-ketoglutarate) at a final concentration of 5 μM for 10 consecutive days, with fresh food provided every two days. Each group consisted of 20 flies. On day 10 of administration, the flies' locomotion ability and the expression of genes Fkbp12, PRAS40, P300 / nej, and cry were assessed.
[0100] 1) Fruit fly survival rate
[0101] We observed that 10 days after administration, there was a difference in the survival rate of the two groups of fruit flies. The survival rate of the NR-AKG group was 35%, while that of the NR-Cl group was 25%, indicating that NR-AKG was more effective in alleviating aging and mortality than NR-Cl.
[0102] 2) Fruit fly locomotion ability
[0103] Because the fruit flies were too old, their climbing ability was generally weakened at this stage. During the test, none of the fruit flies were able to climb on the tube wall. Therefore, the movement ability of the fruit flies was measured by using TrackMate in Fiji to determine the distance of their movement trajectory per minute.
[0104] Experimental data (Figure 7) showed that there was no significant difference in the distance of movement per minute of 50-day-old female flies after continuous administration of NR-Cl or NR-AKG for 10 days.
[0105] 3) Expression of genes Fkbp12, PRAS40, P300 / nej, and cry.
[0106] On day 10 after drug administration, Drosophila were homogenized, and total RNA was extracted using TRIZol reagent and then reverse transcribed. Genes Fkbp12, PRAS40, P300 / nej, and cry were detected using real-time quantitative PCR (qPCR), and normalized using the internal reference gene Rp49.
[0107] The experimental results (Figure 8) show that, compared with the NR-Cl group, the PRAS40 and P300 / nej of the Drosophila in the NR-AKG group showed an upward trend, but the results were not statistically significant. Fkbp12 and cry showed no significant changes at present.
[0108] 2. Young fruit flies were given the drug for 10, 20, 30, and 40 days.
[0109] Selecting just-feathered w 1118 Female flies were divided into five groups: NR-Cl, AKG, NR+AKG, NR-AKG, and a control. The final drug concentration was 5 μM. Drug administration was repeated for 10, 20, 30, and 40 days, with fresh food provided every two days. Climbing ability was assessed on days 10, 20, 30, and 40 after drug administration. Climbing ability, expression of related genes (Fkbp12, PRAS40, P300 / nej, cry), and the ATP / ADP ratio were assessed on days 20 and 40 after drug administration.
[0110] 1) Fruit fly climbing ability
[0111] Ten days after administration (Figure 9), the average percentages of fruit flies that climbed more than 5 cm (>5 cm) within 5 seconds in the control group, NR-Cl group, AKG group, NR+AKG group, and NR-AKG group were 25%, 37.81%, 31.15%, 25.28%, 23.69%, and 28.59%, respectively. The fruit flies in the NR-Cl group had slightly stronger climbing ability, while there were no significant differences among the other groups.
[0112] Twenty days after drug administration (Figure 10), the average percentages of fruit flies climbing more than 5 cm in 5 seconds in the control group, NR-Cl group, AKG group, NR+AKG group, and NR-AKG group were 17.19%, 8.38%, 11.29%, 12.87%, and 11.10%, respectively, showing a significant decrease in climbing ability compared to day 10 after drug administration. Extending the climbing time to 10 seconds, the average percentages of fruit flies climbing more than 5 cm (>5 cm) in the control group, NR-Cl group, AKG group, NR+AKG group, and NR-AKG group were 48.03%, 29.97%, 34.66%, 36.44%, and 47.62%, respectively. The control group was comparable to the NR-AKG group and significantly stronger than the other groups.
[0113] Thirty days after drug administration (Figure 11), except for a very few individuals, all groups of fruit flies struggled to climb more than 5 cm in 5 seconds, a significant decrease in climbing ability compared to day 20 after drug administration. Extending the observation time to 10 seconds, the average percentages of fruit flies climbing more than 5 cm (>5 cm) in the control group, NR-Cl group, AKG group, NR+AKG group, and NR-AKG group were 24.14%, 24.78%, 18.24%, 11.42%, and 17.36%, respectively; the average percentages climbing more than 2.5 cm (>2.5 cm) were 49.34%, 44.90%, 39.32%, 35.14%, and 44.13%, respectively. The NR+AKG group showed weaker climbing ability compared to the NR-AKG group, a result consistent with the data from day 20 after drug administration.
[0114] Forty days after drug administration (Figure 12), the climbing ability of fruit flies in the NR+AKG group was similar to that in the NR-AKG group, but weaker than that in other groups. 2) Expression of genes Fkbp12, PRAS40, P300 / nej, and cry.
[0115] Drosophila were homogenized on days 20 and 40 after drug administration, and total RNA was extracted using TRIZol reagent followed by reverse transcription. Four to five samples were collected per group. Genes Fkbp12, PRAS40, P300 / nej, and cry were detected using real-time quantitative PCR (qPCR), and normalized using the internal reference gene Rp49.
[0116] The experimental results (Figure 13) showed little difference in the expression levels of related genes among the groups after 20 days of drug administration. The expression levels of PRAS40 and P300 were slightly higher in the NR-Cl and AKG groups. The expression level of Fkbp12 showed an increasing trend in the NR-AKG group, but this was not significant at present. The cry expression level was slightly higher in the NR-Cl, AKG, and NR+AKG groups.
[0117] Forty days after drug administration (Figure 13), at the systemic level in Drosophila, aging-related changes were observed, with upregulation of cry and P300 / nej expression, downregulation of Fkbp12 expression, and PRAS40 expression levels comparable to those at day 20 after drug administration. Among the differences between groups, the PRAS40 expression levels in the NR+AKG and NR-AKG groups were significantly higher than in other groups. The expression levels of Fkbp12, cry, and P300 / nej in the NR+AKG group were significantly lower than in the control and single-drug groups, while the expression levels of these genes in the NR-AKG group were higher than in the NR+AKG group.
[0118] 3) ATP / ADP ratio
[0119] The entire body of Drosophila on days 20 and 40 after drug administration was homogenized in buffer solution and tested using an ATP / ADP ratio assay kit, with 7-9 samples per group.
[0120] The test results showed (Figure 14) that there was no significant difference in the ATP / ADP ratio among the groups after 20 days of drug administration. After 40 days of drug administration (Figure 15), the ATP / ADP ratio of the Drosophila group given AKG alone was significantly lower, while the levels of the other groups were comparable.
[0121] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. A nicotinamide riboside organic acid salt, characterized in that, The nicotinamide riboside organic acid salt is nicotinamide riboside alpha-ketoglutarate, and its chemical formula is shown in (Ⅰ); 2. A method for preparing a nicotinamide riboside organic acid salt, characterized in that, The preparation method steps are as follows: S1. Dissolve nicotinamide riboside in a solvent to obtain solution A, which is nicotinamide riboside; S2. Dissolve the organic acid in a solvent, add sodium hydroxide, and mix to obtain solution B, which is an organic acid-basic metal salt; S3. Add the nicotinamide riboside solution to the organic acid-base metal salt solution, and the precipitate produced by the reaction is the nicotinamide riboside organic salt.
3. The preparation method according to claim 2, characterized in that, In step S1, the nicotinamide nucleoside is nicotinamide nucleoside chloride or nicotinamide nucleoside sulfate; In step S2, the organic acid is alpha-ketoglutaric acid; In step S3, the molar ratio of the organic acid-base metal salt to nicotinamide riboside is 1:0.9-1.
1.
4. The use of the nicotinamide riboside organic acid salt as described in claim 1 or the nicotinamide riboside organic acid salt prepared by the method described in claim 2 in the preparation of dietary supplements or nicotinamide nucleoside supplements.
5. A dietary supplement comprising nicotinamide riboside alpha-ketoglutarate and edible excipients; wherein the nicotinamide riboside alpha-ketoglutarate is the nicotinamide riboside organic acid salt of claim 1 or the nicotinamide riboside organic acid salt prepared by the method of claim 2.
6. The dietary supplement as described in claim 5, characterized in that, The edible excipients include galactomannan and vitamin C.
7. The dietary supplement as described in claim 5, characterized in that, The weight ratio of galactomannan to vitamin C is 1:1-2.
8. The dietary supplement as described in claim 5, characterized in that, The weight ratio of the galactomannan to the nicotinamide riboside alpha-ketoglutarate is 1:10-20.
9. A nicotinamide nucleoside supplement, wherein the nicotinamide nucleoside supplement is composed of nicotinamide riboside alpha-ketoglutarate and pharmaceutical excipients; wherein the nicotinamide riboside alpha-ketoglutarate is the nicotinamide riboside organic acid salt of claim 1 or the nicotinamide riboside organic acid salt prepared by the method of claim 2.
10. The drug as described in claim 9, characterized in that, The drug may be used alone or in combination with other drugs.
